OPT - Opthea receives $170M in non-dilutive financing for OPT-302 in wet AMD

• Opthea ( NASDAQ: OPT ) entered into a non-dilutive financing transaction for up to $170M from investment funds working with Launch Therapeutics to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration.
• Launch Tx is the recently formed development company backed by funds managed by global investment firm Carlyle and its life sciences franchise, Abingworth.
• Under agreement terms, the funds managed by Carlyle and Abingworth, in collaboration with Launch Tx, will commit $120M in three installments at fixed time points and retain an option to commit another $50M.
• Opthea retains full worldwide commercial rights for OPT-302 and has the option to prepay its obligations in full at any time.
• "This strategic transaction is expected to fund us through Phase 3 topline data expected in mid-2024 and strengthens our strategic position to maximize the value of OPT-30," CEO Dr Megan Baldwin commented.

For further details see: